- Home
- PLX vs SSSS Comparison
PLX vs SSSS Comparison
Compare PLX & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- SSSS
- Stock Information
- Founded
- PLX 1993
- SSSS 2010
- Country
- PLX Israel
- SSSS United States
- Employees
- PLX N/A
- SSSS N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- SSSS Finance: Consumer Services
- Sector
- PLX Health Care
- SSSS Finance
- Exchange
- PLX Nasdaq
- SSSS Nasdaq
- Market Cap
- PLX 132.5M
- SSSS 143.5M
- IPO Year
- PLX 1998
- SSSS N/A
- Fundamental
- Price
- PLX $1.76
- SSSS $5.83
- Analyst Decision
- PLX
- SSSS Buy
- Analyst Count
- PLX 0
- SSSS 2
- Target Price
- PLX N/A
- SSSS $6.00
- AVG Volume (30 Days)
- PLX 382.4K
- SSSS 245.8K
- Earning Date
- PLX 11-14-2024
- SSSS 11-07-2024
- Dividend Yield
- PLX N/A
- SSSS N/A
- EPS Growth
- PLX N/A
- SSSS N/A
- EPS
- PLX N/A
- SSSS N/A
- Revenue
- PLX $45,667,000.00
- SSSS $5,903,895.00
- Revenue This Year
- PLX N/A
- SSSS N/A
- Revenue Next Year
- PLX $88.94
- SSSS N/A
- P/E Ratio
- PLX N/A
- SSSS N/A
- Revenue Growth
- PLX N/A
- SSSS 5.43
- 52 Week Low
- PLX $0.82
- SSSS $3.32
- 52 Week High
- PLX $1.90
- SSSS $6.65
- Technical
- Relative Strength Index (RSI)
- PLX 62.98
- SSSS 55.63
- Support Level
- PLX $1.60
- SSSS $5.51
- Resistance Level
- PLX $1.83
- SSSS $6.65
- Average True Range (ATR)
- PLX 0.08
- SSSS 0.39
- MACD
- PLX -0.02
- SSSS -0.06
- Stochastic Oscillator
- PLX 71.15
- SSSS 39.71
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.